Showing posts from March, 2024Show all
health-issue
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
https://ift.tt/A0ToFrW from Sanofi - Aventis Groupe https://ift.tt/QMy8utp via IFTTT
Read more
health-issue
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
https://ift.tt/MkUtvnu New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis from …
Read more